Iqbal Singh1, Lokesh Kumar Gautam2, Iqbal R Kaur3. 1. Departments of Surgery (Urology), University College of Medical Sciences (University of Delhi) & GTB Hospital, Shahdara, Dilshad Garden, New Delhi, 110095, Delhi, India. iqbalsinghp@yahoo.co.uk. 2. Departments of Surgery (Urology), University College of Medical Sciences (University of Delhi) & GTB Hospital, Shahdara, Dilshad Garden, New Delhi, 110095, Delhi, India. 3. Departments of Microbiology, University College of Medical Sciences (University of Delhi) & GTB Hospital, New Delhi, 95, India.
Abstract
PURPOSE: To evaluate the effect of cranberry extract (PAC-A ~ proanthocyanidin-A) on the in vitro bacterial properties of uropathogenic (E. coli) and its efficacy/tolerability in patients with subclinical or uncomplicated recurrent UTI (r-UTI). MATERIALS AND METHODS: After obtaining clearance from the ethics committee and administering a written informed consent, 72 patients with r-UTI were enrolled as per protocol (November 2011 to March 2013) in this prospective study, to randomly receive (PAC-A: group I, 36) or (placebo: group II, 36), for 12 weeks. Any change/reduction in the incidence of r-UTI at 12 weeks was construed to be the primary endpoint of this study. RESULTS: After 12 weeks, bacterial adhesion scoring decreased (0.28)/(2.14) in group I/II (p < 0.001); 32/36 (88.8 %) and 2/36 (5.5 %) in groups I and II, respectively, turned MRHA negative (p < 0.001); biofilm (p < 0.01) and bacterial growth (p < 0.001) decreased in group I; microscopic pyuria score was 0.36/2.0 in group I/II (p < 0.001); r-UTI decreased to 33.33 versus 88.89 % in group I/II (p < 0.001); mean subjective dysuria score was 0.19 versus 1.47 in group I/II (p < 0.001), while mean urine pH was 5.88 versus 6.30 in group I/II (p < 0.001). No in vitro antibacterial activity of cranberry could be demonstrated, and no adverse events were noted. CONCLUSIONS: The overall efficacy and tolerability of standardized cranberry extract containing (PAC-A) as a food supplement were superior to placebo in terms of reduced bacterial adhesion; bacterial MRHA negativity; urine pH reduction; and in preventing r-UTI (dysuria, bacteriuria and pyuria). Larger randomized controlled trials are needed to elucidate the precise role, exact dose and optimal duration of PAC-A therapy in patients at risk of r-UTI.
RCT Entities:
PURPOSE: To evaluate the effect of cranberry extract (PAC-A ~ proanthocyanidin-A) on the in vitro bacterial properties of uropathogenic (E. coli) and its efficacy/tolerability in patients with subclinical or uncomplicated recurrent UTI (r-UTI). MATERIALS AND METHODS: After obtaining clearance from the ethics committee and administering a written informed consent, 72 patients with r-UTI were enrolled as per protocol (November 2011 to March 2013) in this prospective study, to randomly receive (PAC-A: group I, 36) or (placebo: group II, 36), for 12 weeks. Any change/reduction in the incidence of r-UTI at 12 weeks was construed to be the primary endpoint of this study. RESULTS: After 12 weeks, bacterial adhesion scoring decreased (0.28)/(2.14) in group I/II (p < 0.001); 32/36 (88.8 %) and 2/36 (5.5 %) in groups I and II, respectively, turned MRHA negative (p < 0.001); biofilm (p < 0.01) and bacterial growth (p < 0.001) decreased in group I; microscopic pyuria score was 0.36/2.0 in group I/II (p < 0.001); r-UTI decreased to 33.33 versus 88.89 % in group I/II (p < 0.001); mean subjective dysuria score was 0.19 versus 1.47 in group I/II (p < 0.001), while mean urine pH was 5.88 versus 6.30 in group I/II (p < 0.001). No in vitro antibacterial activity of cranberry could be demonstrated, and no adverse events were noted. CONCLUSIONS: The overall efficacy and tolerability of standardized cranberry extract containing (PAC-A) as a food supplement were superior to placebo in terms of reduced bacterial adhesion; bacterial MRHA negativity; urine pH reduction; and in preventing r-UTI (dysuria, bacteriuria and pyuria). Larger randomized controlled trials are needed to elucidate the precise role, exact dose and optimal duration of PAC-A therapy in patients at risk of r-UTI.
Authors: Marion E T McMurdo; Linda Y Bissett; Rosemary J G Price; Gabby Phillips; Iain K Crombie Journal: Age Ageing Date: 2005-05 Impact factor: 10.668
Authors: Alexandra E Burleigh; Susan M Benck; Sarah E McAchran; Jess D Reed; Christian G Krueger; Walter J Hopkins Journal: Nutr J Date: 2013-10-18 Impact factor: 3.271
Authors: Timothy J Straub; Wen-Chi Chou; Abigail L Manson; Henry L Schreiber; Bruce J Walker; Christopher A Desjardins; Sinéad B Chapman; Kerrie L Kaspar; Orsalem J Kahsai; Elizabeth Traylor; Karen W Dodson; Meredith A J Hullar; Scott J Hultgren; Christina Khoo; Ashlee M Earl Journal: BMC Microbiol Date: 2021-02-18 Impact factor: 3.605
Authors: Danielle Gomes Santana; Alan Santos Oliveira; Marília Trindade de Santana Souza; José Thiago do Carmo Santos; Neuza Mariko Aymoto Hassimotto; Ana Mara de Oliveira E Silva; Renata Grespan; Enilton Aparecido Camargo Journal: Evid Based Complement Alternat Med Date: 2018-05-14 Impact factor: 2.629